These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29935282)

  • 41. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluvastatin Inhibits Osteoclast Differentiation and Porphyromonas gingivalis Lipopolysaccharide-Induced Alveolar Bone Erosion in Mice.
    Pokhrel NK; Kim YG; Kim JY; Kim HH; Lee Y
    J Periodontol; 2017 Apr; 88(4):390-398. PubMed ID: 27858552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB.
    Quan GH; Wang H; Cao J; Zhang Y; Wu D; Peng Q; Liu N; Sun WC
    Int J Mol Sci; 2015 Dec; 16(12):29496-507. PubMed ID: 26690415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Water extract of Rumex crispus prevents bone loss by inhibiting osteoclastogenesis and inducing osteoblast mineralization.
    Shim KS; Lee B; Ma JY
    BMC Complement Altern Med; 2017 Oct; 17(1):483. PubMed ID: 29070038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uncaria tomentosa reduces osteoclastic bone loss in vivo.
    Lima V; Melo IM; Taira TM; Buitrago LYW; Fonteles CSR; Leal LKAM; Souza ASQ; Almeida TS; Costa Filho RND; Moraes MO; Cunha FQ; Fukada SY
    Phytomedicine; 2020 Dec; 79():153327. PubMed ID: 32920290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
    Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
    Kwak HB; Lee BK; Oh J; Yeon JT; Choi SW; Cho HJ; Lee MS; Kim JJ; Bae JM; Kim SH; Kim HS
    Bone; 2010 Mar; 46(3):724-31. PubMed ID: 19900598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
    Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
    J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
    Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
    Biochem Pharmacol; 2008 Jun; 75(11):2175-82. PubMed ID: 18433733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
    Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
    PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice.
    Park SH; Kim JY; Cheon YH; Baek JM; Ahn SJ; Yoon KH; Lee MS; Oh J
    Phytother Res; 2016 Apr; 30(4):604-12. PubMed ID: 26792397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis.
    Li T; Du Y; Yao H; Zhao B; Wang Z; Chen R; Ji Y; Du M
    Biochem Pharmacol; 2024 Jun; 224():116202. PubMed ID: 38615917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function.
    Zheng T; Wang X; Yim M
    Eur J Pharmacol; 2014 Aug; 737():185-93. PubMed ID: 24842191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.